DK1536777T3 - Anvendelse af NF-KB-inhibitorer til behandling af mastitis - Google Patents

Anvendelse af NF-KB-inhibitorer til behandling af mastitis

Info

Publication number
DK1536777T3
DK1536777T3 DK03753579T DK03753579T DK1536777T3 DK 1536777 T3 DK1536777 T3 DK 1536777T3 DK 03753579 T DK03753579 T DK 03753579T DK 03753579 T DK03753579 T DK 03753579T DK 1536777 T3 DK1536777 T3 DK 1536777T3
Authority
DK
Denmark
Prior art keywords
mastitis
inhibitors
treatment
kappa
medicament
Prior art date
Application number
DK03753579T
Other languages
English (en)
Inventor
Delphine Boulanger
Fabrice Bureau
Pierre Lekeux
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK1536777T3 publication Critical patent/DK1536777T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK03753579T 2002-08-14 2003-08-12 Anvendelse af NF-KB-inhibitorer til behandling af mastitis DK1536777T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02078352 2002-08-14
PCT/EP2003/050373 WO2004016253A1 (en) 2002-08-14 2003-08-12 Use of nf-kappa b inhibitors for the treatment of mastitis

Publications (1)

Publication Number Publication Date
DK1536777T3 true DK1536777T3 (da) 2007-06-04

Family

ID=31725450

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03753579T DK1536777T3 (da) 2002-08-14 2003-08-12 Anvendelse af NF-KB-inhibitorer til behandling af mastitis

Country Status (10)

Country Link
US (1) US20060240011A1 (da)
EP (1) EP1536777B1 (da)
JP (1) JP2005539028A (da)
AT (1) ATE353638T1 (da)
AU (1) AU2003271747B2 (da)
CA (1) CA2495068A1 (da)
DE (1) DE60311825T2 (da)
DK (1) DK1536777T3 (da)
ES (1) ES2282658T3 (da)
WO (1) WO2004016253A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
WO2015000022A1 (en) * 2013-07-05 2015-01-08 Adelaide Research & Innovation Pty Ltd Treatment and prevention of mastitis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
EP1165092A1 (en) * 1999-03-22 2002-01-02 Charterhouse Therapeutics Ltd. Cyclopentanone derivatives and their use
GB9922505D0 (en) * 1999-09-24 1999-11-24 Kennedy Rheumatology Inst Therapeutic methods and compounds

Also Published As

Publication number Publication date
ES2282658T3 (es) 2007-10-16
ATE353638T1 (de) 2007-03-15
US20060240011A1 (en) 2006-10-26
DE60311825T2 (de) 2007-12-06
CA2495068A1 (en) 2004-02-26
EP1536777B1 (en) 2007-02-14
DE60311825D1 (de) 2007-03-29
AU2003271747B2 (en) 2008-09-11
AU2003271747A1 (en) 2004-03-03
JP2005539028A (ja) 2005-12-22
WO2004016253A1 (en) 2004-02-26
EP1536777A1 (en) 2005-06-08

Similar Documents

Publication Publication Date Title
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
ATE520674T1 (de) Natriumkanalblocker
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
CY1105082T1 (el) Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
DE602004020334D1 (de) Komplementinhibitoren aus zecken
NO20043367L (no) Oralt farmasoytisk preparat
DK1450606T3 (da) Synergistiske sammensætninger til behandling af såsæd
ECSP044981A (es) Composicion oftalmica que comprende ascomicina
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
ATE273699T1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
DK1443938T3 (da) Dosisenhed omfattende en prostaglantinanalog til behandling af forstoppelse
DK1487506T3 (da) Præparat til sårheling og forhindring af bandagevedhæftning på såret
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
ATE443044T1 (de) Tace inhibitoren
FR2820610B1 (fr) Ensemble pour le palissage, notamment des vignes
DK1603584T3 (da) Aplidine til behandling af multipelt myelom
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
DK1536777T3 (da) Anvendelse af NF-KB-inhibitorer til behandling af mastitis
SE0002739D0 (sv) New use
SE0200198D0 (sv) New use
TW200509921A (en) Alkaline salts
DK1513529T3 (da) Tredobbelte monoamin-genoptagelsesinhibitorer til behandling af kronisk smerte
DE50309647D1 (de) Ng fibrotischer erkrankungen